A relative in vivo FDGlcU conversion efficiency was calculated by dividing the FDGlcU tumor fluorescence (from Fig. 8D) by the beta-glucuronidase activity in tumor lysates (from Fig. 8B). The gene discussed is GUSB; the disease is neoplasm.